Cue Biopharma
Cue Biopharma

Cue Biopharma

Biotechnology
WebsiteInvestor RelationsSEC
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

$229.8M

Market Cap • 9/15/2026

2014

(12 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

6,1

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

229,8M

EV

221,3M

EV/Revenue

5,9

EV/EBITDA

-2,3

EV/EBIT

-2,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-18,4%

Total Yield

-18,4%

Payout

0%

Retained Earnings

-526,7M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

205%

Capex/Revenue

0,3%

Capex/D&A

8,9%

Capex/OCF

-0,2%

SBC/OCF

—

% PPE

10,5%

% Goodwill

0%

ROE

65,3%

ROIC

—

Growth

CAGR Revenue 5Y

47,1%

CAGR Op. Income 5Y

17,6%

CAGR Net Income 5Y

30,2%

CAGR EPS 5Y

-9%

CAGR OCF 5Y

6,7%

Leverage

N.D./EBITDA

0,1

Debt/Equity

0%

Current Ratio

1,2

Quick Ratio

1,2

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium